|1.||Kleinrok, Zdzislaw: 2 articles (01/2004 - 08/2003)|
|2.||Borowicz, Kinga K: 2 articles (01/2004 - 08/2003)|
|3.||van der Meer, Klaas: 1 article (04/2013)|
|4.||Roorda, Carriene: 1 article (04/2013)|
|5.||Groenhof, Feikje: 1 article (04/2013)|
|6.||de Bock, Geertruida H: 1 article (04/2013)|
|7.||Berendsen, Annette J: 1 article (04/2013)|
|8.||Ciarlo, Monica: 1 article (08/2012)|
|9.||Ferrari, Nicoletta: 1 article (08/2012)|
|10.||Barbieri, Ottavia: 1 article (08/2012)|
|2.||Invasive Hydatidiform Mole (Invasive Mole)
08/01/2012 - "The extent of AKT phosphorylation and hnRNP K, AR and β-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists."
01/01/2010 - "In this system, we evaluated the effects of kinase inhibitors and hormone antagonists on tumor growth. "
10/01/1994 - "Autonomous AF3 function may explain the unexpected transactivating actions of antiprogestin-occupied hPRB, an issue of importance in hormone-resistant breast cancers and in tissue-specific agonist-like effects of hormone antagonists."
04/20/1994 - "Our results raise the possibility that compounds that reduce GH output or interfere with GH action, such as somatostatin analogues, GH antagonists, IGF antagonists, and GH-releasing hormone antagonists, may suppress metastatic behavior of certain neoplasms."
10/01/1993 - "[Hormone antagonists: discovery of steroid hormones for specific cancer therapy]."
|4.||Breast Neoplasms (Breast Cancer)
08/24/1951 - "[Effect of hormone antagonists on lenticular metastases in cancer of the breast]."
04/01/2013 - "More patients than women from the reference population had face-to-face contacts for reasons related to breast cancer or were prescribed hormone antagonists and aromatase inhibitors to treat breast cancer. "
08/01/2001 - "Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer."
07/01/2001 - "We conclude that in light of their novel mechanism of anti-hormone action, consideration should be given to examining the activity of 17AAG and other Hsp90-binding agents in patients with refractory breast cancer in future clinical trials, either alone or in combination with conventional hormone antagonists."
|5.||Wounds and Injuries (Trauma)
05/01/2003 - "Furthermore, experimental studies have demonstrated the use of hormones, hormone antagonists, sex steroids, and receptor antagonists as salutary adjuncts, without any adverse effects on gastrointestinal, hepatic, and renal functions, for restoring the depressed immune and cardiovascular responses after trauma-hemorrhage. "
|2.||Mifepristone (RU 486)
|4.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|9.||Anticonvulsants (Antiepileptic Drugs)
|2.||Drug Therapy (Chemotherapy)